BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 14, 2007
View Archived Issues
Ambit's Series D Raises $50M For Kinase Inhibitor Program
With one kinase inhibitor in the clinic and two more in the queue, Ambit Biosciences Corp. raised $49.3 million in a Series D financing round. (BioWorld Today)
Read More
Competition For Few Compounds Drives Up Deal Costs, Complexity
Read More
Acambis Partners West Nile Vaccine In $80M Sanofi Deal
Read More
Smoke Clears; Pfizer Paying Nektar $135M In Exubera Deal
Read More
AVAX Starts Pivotal Testing With M-Vax Cancer Vaccine
Read More
VaxGen, Raven Get 'Fresh Start' Via Merger To Focus On Cancer
Read More
Other News To Note
Read More
Clinic Roundup
Read More